COMP <GO>
CUVL vs TMO // FORWARD P/E MULTIPLE
Clinuvel Pharmaceuticals Limited (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CUVL 7
— TMO 3
▲ FORWARD P/E MULTIPLE LEADER: CUVL
LAST: $5.15 (+1.58%) • MKT CAP: $257.8M
forward-pe
10.3x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CUVL VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CUVL | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 9.30% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.7x | 30.4x | -20.70 | CUVL | /valuation <GO> |
| Free Cash Flow Yield | 10.51% | 2.40% | +8.11 | CUVL | /fcf-yield <GO> |
| Operating Margin | 43.40% | 17.40% | +26.00 | CUVL | /operating-margins <GO> |
| Net Profit Margin | 37.80% | 15.10% | +22.70 | CUVL | /net-margins <GO> |
| Revenue Growth (YoY) | 5.50% | 3.90% | +1.60 | CUVL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.66% | 0.24% | +0.42 | CUVL | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.50 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.7 | 62.9 | -25.23 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 10.3x | 36.3x | -26.00 | CUVL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $257.8M | $262.22B | -$261.96B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CUVL REV | TMO REV | CUVL GROSS % | TMO GROSS % | CUVL FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.1M | $44.56B | 81.2% | — | $27.1M | $6.29B |
| FY 2024 | $57.9M | $42.88B | 81.5% | — | $20.1M | $7.27B |
| FY 2023 | — | $42.86B | — | — | — | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CUVL // BETA —
TMO // BETA 0.94